0 Replies
As scientists gain a greater understanding of RNAi capabilities and limitations, and as the RNAi market continues to grow rapidly, more varied RNAi products and selections are becoming commercially available. ... Contine Reading & Discuss→
0 Replies
As scientists gain a greater understanding of RNAi capabilities and limitations, and as the RNAi market continues to grow rapidly, more varied RNAi products and selections are becoming commercially available. ... Contine Reading & Discuss→
0 Replies
BOULDER, Colo., October 26, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced today that they have entered into sponsored research and licensing agreements to collaborate on miRNA... Contine Reading & Discuss→
0 Replies
Stories include:
Watertown, MA-based Dicerna Pharmaceuticals says it's added another $4 million in financing, bringing the developer's total haul to $29 million. GlaxoSmithKline's venture arm SR One joined the original group of investors which included Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates.
Dicerna was a 2010 Fierce 15... Contine Reading & Discuss→
0 Replies
Stories include:
@FierceBiotech: Why are women thriving in the top ranks of biotech? Article
Special Report: Pharma's Biggest Flops. Report Contine Reading & Discuss→
0 Replies
Stories include:
FierceBiotech Research alerts lab research professionals on the latest scientific breakthroughs in drug discovery and development. Get your free weekly email briefing today!
Email address: *
About View Sample Privacy
Cancer Research Contine Reading & Discuss→
